Please provide your email address to receive an email when new articles are posted on . Hypoactive sexual desire disorder is lack of motivation, desire, response or inability to keep interest in sex.

Please provide your email address to receive an email when new articles are posted on . Many midlife women experience hypoactive sexual desire disorder, which can impact both relationships and mental ...

Sexual desire disorder is a psychiatric condition marked by a lack of desire for sexual activity over a prolonged period. In the DSM-5, sexual desire disorder has been broken down into two separate ...

For the first time, sexual medicine experts have created treatment guidelines and recommendations for women who experience low sexual desire or Hypoactive Sexual Desire Disorder (HSDD), a common yet ...

In 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was published with a major revision to the sexual dysfunction categories, and the diagnosis of female ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

The FDA finally approved Addyi, the controversial drug known as the female Viagra, for the treatment of flagging sexual desire in women. Efforts to make such a drug available to women have been ...

NEW YORK (Reuters Health) - The antidepressant bupropion may hold promise for improving symptoms in younger women diagnosed with so-called hypoactive sexual desire disorder, a small study suggests.

Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs ...

Flibanserin (Addyi), the drug manufactured by Sprout Pharmaceuticals for the treatment of hypoactive sexual desire disorder (HSDD), received approval from the FDA for use in postmenopausal women up to ...

The US Food and Drug Administration (FDA) today approved bremelanotide (Vyleesi, AMAG Pharmaceuticals), a first-in-class melanocortin 4 receptor agonist for hypoactive sexual desire disorder (HSDD) in ...